Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?

Archives of Ophthalmology

Volumn 111, Issue 1, 1993, Pages 96-103

  Rossetti, Luca ^a,b   Marchetti, Ilaria ^a   Orzalesi, Nicola ^a   Scorpiglione, Nicola ^c   Torri, Valter ^b   Liberati, Alessandro ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Lab Clin Pharmacol and Epidemiol   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT;

DRUG EFFICACY; EYE PROTECTION; FOLLOW UP; GLAUCOMA; INTRAOCULAR PRESSURE ABNORMALITY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT PLANNING; VISUAL FIELD DEFECT;

CLINICAL PROTOCOLS; GLAUCOMA, OPEN-ANGLE; HUMAN; INTRAOCULAR PRESSURE; PLACEBOS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME; VISUAL FIELDS;

EID: 0027511336     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.1993.01090010100034     Document Type: Article

References (120)

1. 1. Sommer A, Tilsch J, Katz J, et al., Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090-1095.
2. 2. Sponsel WE. Tonometry in question: can visual screening tests play a more decisive role in glaucoma diagnosis and management? Surv Ophthalmol. 1989;33(suppl):291-300.
3. 3. Olson RJ. How exposed are we? Is there a better way? Arch Ophthalmol. 1989;107:1131.
4. 4. Lichter PR. A wolf in sheep's clothing. Ophthalmology. 1988;95:149-150.
5. 5. Hoyng PF, Verbey NL. Timolol vs guanethidine-epinephrine formulations in the treatment of glaucoma. Arch Ophthalmol. 1984;102:1788-1793.
6. 6. Martin XD, Rabineau PA. Intraocular pressure effects of timolol after unilateral instillation. Ophthalmology. 1988;95:1620-1623.
7. 7. Novack GD, Kelley E, Lue JC. A multicenter evaluation of levobunolol (Vistagan) in Germany. Ophthalmologica. 1988;197:90-96.
8. 8. Wandel T, Fishman D, Novack GD, Kelley E, Chen KK. Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Ophthalmology. 1988;95:252-255.
9. 9. The Levobunolol Study Group. The effect of disease severity on the success rate of beta-blocker therapy in glaucoma. Glaucoma. 1989;11:109-113.
10. 10. Goldberg HS, Feldman F, Cohen MM, Clark L. Effect of topical indomethacin and timolol maleate on intraocular pressure in normal subjects. Am J Ophthalmol. 1985;99:576-578.
11. 11. Lee DA, Topper JE, Brubaker RF. Effect of clonidine on aqueous humor flow in normal human eyes. Exp Eye Res. 1984;38:239-246.
12. 12. Lippa E, von Denffer HA, Hofmann HM, Brunner-Ferber FL. Local tolerance and activity of MK-927, a novel topical carbonic anhidrase inhibitor. Arch Ophthalmol. 1988;106:1694-1696.
13. 13. Mottow-Lippa LS, Lippa EA, Naidoff MA, Clementi R, Bjornsson T, Jones K. 0.008% timolol ophthalmic solution: a minimal-effect dose in a normal volunteer model. Arch Ophthalmol. 1990;108:61-64.
14. 14. Arrigg CA, Epstein DL, Giovanoni R, Grant VM. The influence of supplemental sodium acetate on carbonic anhidrase inhibitor-induced side effects. Arch Ophthalmol. 1981;99:1969-1972.
15. 15. Blondeau P, Coté M. Cardiovascular effects of epinephrine and dipivefrin in patients using timolol: a single-dose study. Can J Ophthalmol. 1984;19:29-32.
16. 16. Camras CB, Feldman SG, Podos SM, Christensen RE, Gardner SK, Fazio DT. Inhibition of epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am J Ophthalmol. 1985;100:169-175.
17. 17. Abrams DA, Robin AL, Crandall AS, et al. A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure. Am J Ophthalmol. 1989;108:230-237.
18. 18. Berson FG, Epstein DL, Grant WM, Hutchinson BT, Dobbs PC. Acetazolamide dosage forms in the treatment of glaucoma. Arch Ophthalmol. 1980;98:1051-1054.
19. 19. Bron AM, Lippa EA, Hofman HM, et al. MK-927: a topically effective carbonic anhydrase inhibitor in patients. Arch Ophthalmol. 1989;107:1143-1146.
20. 20. Chou G, Chou WB, Merritt JC, Martin M, Helms R. Random clinical trial of dipivefrin and timolol in Chinese primary open angle glaucoma: placebo-controlled single-dose effect on intraocular pressure. Glaucoma. 1987;9:122-124.
21. 21. Clark JB, Brooks AMV, Harper CA, Mantzioros N, Gillies WE. A comparison of the efficacy of betaxolol and timolol in ocular hypertension with or without adrenaline. Aust N Z J Ophthalmol. 1989;17:173-177.
22. 22. Cyrlin MN, Thomas JV, Epstein DL. Additive effect of epinephrine to timolol therapy in primary open-angle glaucoma. Arch Ophthalmol. 1982;100:414-418.
23. 23. Duff GR. A double-masked cross-over study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmol (Copenh). 1987;65:618-621.
24. 24. Duff GR, Graham PA. A double cross-over trial comparing the effects of topical carteolol and placebo on intraocular pressure. Br J Ophthalmol. 1988;72:27-28.
25. 25. Duff GR, Newcombe RG. The 12-hour control of intraocular pressure on carteolol 2% twice daily. Br J Ophthalmol. 1988;72:890-891.
26. 26. Foster TS, Kielar RA, Blouin RA, et al. Maintenance of previously controlled intraocular pressure in patients with glaucoma or ocular hypertension: comparison of four regimens of methazolamide. Glaucoma. 1989;11:67-71.
27. 27. Goldberg I, Ashburn FS, Palmberg PF, Kass MA, Becker B. Timolol and epinephrine: a clinical study of ocular interactions. Arch Ophthalmol. Batenhorst RL, Panebianco DL, Wilensky JT. 1980;98:484-486.
28. 28. Higginbotham EJ, Kass MA, Lippa EA, MK-927: a topical carbonic anhydrase inhibitor: dose response and duration of action. Arch Ophthalmol. 1990;108:65-68.
29. 29. Hitchings RA, Glover D. Adrenaline 1% combined with guanethidine 1% versus adrenaline 1%: a randomized prospective double-blind cross-over study. Br J Ophthalmol. 1982;66:247-249.
30. 30. Hodapp E, Kolker AE, Kass MA, Goldberg I, Becker B, Gordon M. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol. 1981;99:1208-1211.
31. 31. Jampel HD, Robin AL, Quigley HA, Pollack IP. Apraclonidine: a one-week dose-response study. Arch Ophthalmol. 1988;106:1069-1073.
32. 32. Joyce PW, Mills KB. Comparison of the effect of acetazolamide tablets and sustets on diumal intraocular pressure in patients with chronic simple glaucoma. Br J Ophthalmol. 1990;74:413-416.
33. 33. Mills KB, Hercules B, English M. Two blind randomized crossover trials in the treatment of primary open angle glaucoma: comparing both guanethidine 3 percent with adrenaline 0.5 percent and guanethidine 1 percent with adrenaline 0.2 percent, combined in single drop form, with timolol 0.25 percent. Eye. 1981;101:397.
34. 34. Mills KB, Jacobs NJ, Vogel R. A study of the effects of four concentrations of D-timolol, 0.25% L-timolol and placebo on intraocular pressure on patients with raised intraocular pressure. Br J Ophthalmol. 1988;72:469-472.
35. 35. Mills KB, Wright G. A blind randomized crossover trial comparing metipranolol 0.3% with timolol 0.25% in open angle glaucoma: a pilot study. Br J Ophthalmol. 1986;70:39-42.
36. 36. Morrison JC, Robin AL. Adjunctive glaucoma therapy: a comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology. 1989;96:3-7.
37. 37. Murray A, Glover D, Hitchings R. Low-dose combined guanethidine 1% and adrenaline 0.5% in the treatment of chronic simple glaucoma: a prospective study. Br J Ophthalmol. 1981;65:533-535.
38. 38. Nielsen NV, Eriksen JS. Timolol and metoprolol in glaucoma: a comparison of the ocular hypotensive effect, local and systemic tolerance. Acta Ophthalmol (Copenh). 1981;59:336-346.
39. 39. O'Connor MA, Mooney DJ. The additional pressure-lowering effect in patients with glaucoma of pilocarpine 2 percent, adrenaline 1 percent, or guanethidine 3 percent with adrenaline 0.5 percent: a double-blind crossover study. Eye. 1983;103:588-592.
40. 40. Ohrstrom A, Kattstrom O. A combination of oral and topical beta-blockers with additive effects on intraocular pressure. Acta Ophthalmol (Copenh). 1983;61:1021-10289.
41. 41. Petursson G, Cole R, Hanna C. Treatment of glaucoma using minidrops of clonidine. Arch Ophthalmol. 1984;102:1180-1181.
42. 42. Reynolds PM, Crick RP. A study of three different dose schedules of oral atenolol in raised intraocular pressure. Glaucoma. 1989;11:23-30.
43. 43. Romano JH, Nagasubramanian S, Poinoosawny D. Double-masked crossover comparison of Ganda 1.02 (guanethidine 1% and adrenaline 0.2% mixture) with gutt adrenaline 1% (Simplene 1%) and pilocarpine 1% (Sno-pilo 1%). Br J Ophthalmol. 1981;65:50-52.
44. 44. Serle JB, Lustgarten JS, Lippa EA, Camras CB, Panebianco DL, Podos SM. MK927, a topical carbonic anhydrase inhibitor: dose response and reproducibility. Arch Ophthalmol. 1990;108:838-841.
45. 45. Smith RJ, Nagasubramanian S, Watkins R, Poinoosawny D. Addition of timolol maleate to routine medical therapy: a clinical trial. Br J Ophthalmol. 1980;64:779-781.
46. 46. Stenkula E, Wetrell K. A dose-response study of oral atenolol administered once daily in patients with raised intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 1982;218:96-98.
47. 47. Tsoy EA, Meekings BB, Shields MB. Comparison of two treatment schedules for combined timolol and dipivefrin therapy. Am J Ophthalmol. 1986;102:320-324.
48. 48. Tutton MK, Smith RJH. Comparison of ocular hypotensive effects of 3 dosages of oral atenolol. Br J Ophthalmol. 1983;67:664-667.
49. 49. Allen CA, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol. 1986;101:535-541.
50. 50. Andreasson S, Moller Jensen K. Effect of pindolol on intraocular pressure in glaucoma: pilot study and a randomized comparison with timolol. Br J Ophthalmol. 1983;67:228-230.
51. 51. Berry DP Jr, Van Buskirk EM, Shields B. Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol. 1984;102:42-45.
52. 52. Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman ED. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol. 1985;103:379-382.
53. 53. Boozman FW III, Carriker R, Foerster R, Allen RC, Novack GD, Batoosingh AL. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure. Arch Ophthalmol. 1988;106:614-618.
54. 54. Charap AD, Shin DH, Petursson G, et al. Effect of varying drop size on the efficacy and safety of a topical beta-blocker. Ann Ophthalmol. 1989;21:351-357.
55. 55. Cinotti A, Cinotti D, Grant W, et al. Levobunolol vs timolol for open angle glaucoma and ocular hypertension. Am J Ophthalmol. 1985;99:11-17.
56. 56. Duzman E, Ober M, Scharrer A, Leopold IH. A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure. Am J Ophthalmol. 1982;94:318-327.
57. 57. Feghali JG, Kaufman PL, Radius RL, Mandell AI. A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. Acta Ophthalmol (Copenh). 1988;66:180-186.
58. 58. Geyer O, Lazar M, Novack GD, Lue JC, Duzman E. Levobunolol compared with timolol for the control of elevated intraocular pressure. Ann Ophthalmol. 1986;18:289-292.
59. 59. Krieglstein GK, Novack GD, Voepel E, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br J Ophthalmol. 1987;71:250-253.
60. 60. The Levobunolol Study Group. Levobunolol: a four-year study of efficacy and safety in glaucoma treatment. Ophthalmology. 1989;96:642-645.
61. 61. Levy NS, Boone L, Ellis E. A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy. Glaucoma. 1985;7:54-62.
62. 62. Long DA, Johns GE, Mullen RS, et al. Levobunolol and betaxolol: a double-masked-controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology. 1988;95:735-741.
63. 63. Long D, Zimmermann T, Spaeth G, Novack G, Burke PJ, Duzman E. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open angle glaucoma or ocular hypertension. Am J Ophthalmol. 1985;99:18-22.
64. 64. Mills KB. Blind randomized noncrossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma. Br J Ophthalmol. 1983;67:216-219.
65. 65. Novack GD, David R, Lee PF, Freeman MI, Duzman E, Batoosingh AL. Effect of changing medication regimens in glaucoma patients. Ophthalmologica. 1988;196:23-28.
66. 66. Ober M, Scharrer A, David R, et al. Long-term ocular hypotensive effect of levobunolol: results of one-year study. Br J Ophthalmol. 1985;69:593-599.
67. 67. Pecori Giraldi J, Boles Carenini B, Virno M, et al. Double-blind study of levobunolol versus timolol in open angle glaucoma. In: Proceedings of the 25th International Congress of Ophthalmology; May 4-10, 1986, Rome, Italy. Milan, Italy: Kugler & Ghedini; 1987:1594-1597.
68. 68. Rakofsky SI, Lazar M, Almog Y, et al. Efficacy and safety of once daily levobunolol for glaucoma therapy. Can J Ophthalmol. 1989;24:2-6.
69. 69. Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once daily and twice daily levobunolol treatment. Ophthalmology. 1989;96:8-11.
70. 70. Rolando M, Murialdo U, Dolci A, Sanfelici G, Calabria G. New beta-blockers: comparison of efficacy versus timolol maleate. Glaucoma. 1989;11:27-30.
71. 71. Scharrer A, Ober M. The comfort of levobunolol and metipranolol in patients with elevated intraocular pressure. In: Proceedings of the 25th International Congress of Ophthalmology, May 4-10, 1986, Rome, Italy. Milan, Italy: Kugler & Ghedini; 1987:1601-1605.
72. 72. Scharrer A, Ober M. Timolol vs befunolol: intraocular pressure and side effects. In: Proceedings of the 25th International Congress of Ophthalmology; May 4-10, 1986, Rome, Italy. Milan, Italy: Kugler & Ghedini; 1987:1598-1600.
73. 73. Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol. 1988;105:150-154.
74. 74. Seamone C, LeBlanc R, Saheb N, Novack G. Efficacy of twice daily levobunolol in the treatment of elevated intraocular pressure. Can J Ophthalmol. 1988;23:168-170.
75. 75. Soll DB. Evaluation of timolol in chronic open angle glaucoma: once daily vs twice a day. Arch Ophthalmol. 1980;98:2178-2181.
76. 76. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol: a six-month double-blind comparison. Arch Ophthalmol. 1986;104:46-48.
77. 77. Uusitalo RJ, Pakama A, Stjernschantz J. A study of the efficacy of two commercial preparations of timolol maleate with special reference to side effects. Acta Ophthalmol (Copenh). 1985;63:634-641.
78. 78. Vogel R, Tipping R, Kulaga SF, Cline-schmidt CM, the Timolol-Betaxolol Study Group. Changing therapy from timolol to betaxolol: effect on intraocular pressure in selected patients with glaucoma. Arch Ophthalmol. 1989;107:1303-1307.
79. 79. Wandel T, Charap AD, Lewis RA, et al. Glaucoma treatment with once daily levobunolol. Am J Ophthalmol. 1986;:298-304.
80. 80. Alexander DW, Berson FG, Epstein DL. A clinical trial of timolol and epinephrine in the treatment of primary open angle glaucoma. Ophthalmology. 1988;95:247-251.
81. 81. Boger WP III, Steinert RF, Puliafito CA, Pavan-Langstom D. Clinical trial comparing timolol ophthalmic solution to pilocarpine in open angle glaucoma. Am J Ophthalmol. 1978;86:8-18.
82. 82. Calissendorff B, Maren N, Wettrell K, Otberg A. Timolol versus pilocarpine separately or combined with acetazolamide effects on intraocular pressure. Acta Ophthalmol (Copenh). 1980;58:624-632.
83. 83. Dallas NL, Sponsel WE, Hobley AJ. A comparative evaluation of timolol maleate and pilocarpine in the treatment of chronic open angle glaucoma. Eye. 1988;2:243-249.
84. 84. Korey MS, Hodapp E, Kass MA, Goldeberg I, Gordon M, Becker B. Timolol and epinephrine: long-term evaluation of concurrent administration. Arch Ophthalmol. 1982;100:742-745.
85. 85. Ohrstrom A, Kattstrom O. Interaction of timolol and adrenaline. Br J Ophthalmol. 1981;65:53-55.
86. 86. Parrow KA, Hong YJ, Shin DH, Shi DX, McCarty B. Is it worthwhile to add the dipivefrine HCl 0.1% to topical β1-β2-blocker therapy? Ophthalmology. 1989;96:1338-1342.
87. 87. Sonntag JR, Brindley GO, Shields B, Arafat IT, Phelps CD. Timolol and epinephrine: comparison of efficacy and side-effects. Arch Ophthalmol. 1979;97:273-277.
88. 88. Villumsen J, Alm A. The effect of adding prostaglandin F2α-isopropyl ester to timolol in patients with open angle glaucoma. Arch Ophthalmol. 1990;108:1102-1105.
89. 89. Airaksinen PJ, Valkonen R, Stenborg T, et al. A double-masked study of timolol and pilocarpine combined. Am J Ophthalmol. 1987;104:587-590.
90. 90. Allen RC, Robin AL, Long D, Novack GD, Lue JC, Kaplan G. A combination of levobunolol and dipivefrin for the treatment of glaucoma. Arch Ophthalmol. 1988;106:904-907.
91. 91. Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch Ophthalmol. 1986;104:1178-1184.
92. 92. Hovding G, Aasved H. Timolol/pilocarpine combination eye drops in open angle glaucoma and in ocular hypertension: a controlled randomized study. Acta Ophthalmol (Copenh). 1987;65:594-601.
93. 93. Knupp JA, Shields MB, Mandell AI, Hurvitz L, Spaeth GL. Combined timolol and epinephrine therapy for open angle glaucoma. Surv Ophthalmol. 1983;28:280-284.
94. 94. Mills KB, Vogel R, Jacobs N. Timolol and guanethidine plus adrenaline in combination in the treatment of chronic open angle glaucoma. Eye. 1985;104:621-624.
95. 95. Soderstrom MB, Wallin O, Granstrom PA, Thorburn W. Timolol-pilocarpine combined vs timolol and pilocarpine given separately. Am J Ophthalmol. 1989;107:465-470.
96. 96. Thomas JV, Epstein DL. Timolol and epinephrine in primary open angle glaucoma: transient additive effect. Arch Ophthalmol. 1981;99:91-95.
97. 97. Kass MA, Mandel AI, Goldberg I, Paine M, Becker B. Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study. Arch Ophthalmol. 1979;97:1875-1866.
98. 98. Lichter PR, Musch DC, Medzihradsky F, Standardi CL. Intraocular pressure effects of carbonic anhydrase inhibitors in primary open angle glaucoma. Am J Ophthalmol. 1989;107:11-17.
99. 99. Mills KB, Jacobs NA. A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (Propine) 0.1% in the treatment of open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1988;72:465-468.
100. 100. Tiedeman JS, Shields MB, Weber IA, et al. Effect of synthetic cannabinoids on elevated intraocular pressure. Ophthalmology. 1981;88:270-277.
101. 101. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol. 1984;102:539-540.
102. 102. Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96:1329-1337.
103. 103. Elman J, Caprioli J, Rosanelli G Jr, et al. Celiprolol versus timolol and placebo: a two-week double-blind comparison. J Ocul Pharmacol. 1987;3:5-9.
104. 104. Feghali JG, Kaufmann PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a β1-adrenergic antagonist. Am J Ophthalmol. 1985;100:777-782.
105. 105. Keates EU, Stone R. The effect of ditimolol on intraocular pressure with patients with ocular hypertension. Am J Ophthalmol. 1984;98:73-78.
106. 106. Lippa EL, Aasve H, Airaksinen J, et al. Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927. Arch Ophthalmol. 1991;109:46-49.
107. 107. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 vs sezolamide: comparative efficacy of two topically carbonic anhydrase inhibitors. Ophthalmology. 1991;98:308-313.
108. 108. Partamian LG, Kass MA, Gordon M. A dose-response study on the effect of levobunolol on ocular hypertension. Am J Ophthalmol. 1983;95:229-232.
109. 109. Pfeiffer N, Hennekes R, Lippa EA, Grehn F, Garus H, Brunner-Ferber FL. A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol. 1990;74:405-408.
110. 110. Zimmermann TJ, Kass MA, Yablonsky ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979;97:656-658.
111. 111. Bensinger RE, Keates EU, Gofman JD, Novack GD, Duzman E. Levobunolol: a three-month efficacy study in the treatment of glaucoma and ocular hypertension. Arch Ophthalmol. 1985;103:375-378.
112. 112. Chauan BC, Drance SM, Douglas GR. The time course of intraocular pressure in timololtreated and untreated glaucoma suspects. Am J Ophthalmol. 1989;107:471-475.
113. 113. Epstein DL, Krug JH, Hertzmark E, Remis LL, Edelstein DJ. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucona suspects. Ophthalmology. 1989;96:1460-1467.
114. 114. Holmin C, Thorbum W, Krakau CET. Treatment versus no treatment in chronic open angle glaucoma. Acta Ophthalmol (Copenh). 1988;66:170-173.
115. 115. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: a randomized double-masked long-term clinical trial. Arch Ophthalmol. 1989;107:1590-1598.
116. 116. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology. 1991;98:301-307.
117. 117. Hillis A. Surrogate end points in clinical trials: ophthalmologic disorders. Stat Med. 1989;8:427-430.
118. 118. Nicolucci A, Grilli R, Alexanian AA, Apolone G, Torri V, Liberati A. Quality, evolution, and clinical implications of randomized control trials on the treatment of lung cancer: a lost opportunity for meta-analysis. JAMA. 1989;262:2101-2107.
119. 119. Buyse M, Zeleniuch-Jaquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA. 1988;259:3571-3578.
120. 120. Eddy MD, Billings J. The quality of medical evidence: implications for quality of care. Health Aff (Millwood). 1988; spring: 19-32.